CDC's Recommendation for Hepatitis C Testing in Infants Exposed During Perinatal Period


The CDC recommends HCV testing for perinatally exposed infants and children to address the increasing incidence of hepatitis C among reproductive-age individuals, focusing on early detection and appropriate care.

CDC    (Adobe Stock unknown)


(Adobe Stock unknown)

CDC Recommends HCV Testing of Perinatally Exposed Infants Children The Centers for Disease Control and Prevention (CDC) has issued new recommendations1 for hepatitis C virus (HCV) testing of all perinatally exposed infants and children and for referral of those testing positive to appropriate care and the curative treatments that are approved for children as young as 3 years.

"Proper identification of perinatally infected children, referral to care, and curative treatments are critical to achieving the goal of hepatitis C elimination," declared Lakshmi Panagiotakopoulos, MD, Division of Viral Hepatitis, National Center for HIV, Viral Hepatitis, sexually transmitted diseases (STD), and tuberculosis (TB) Prevention, CDC, Atlanta, GA, and colleagues.

Four new recommendations were issued to address a greater than three-fold increase in HCV incidence among persons of reproductive age during the period of 2010-2021 and the 6 to 7 percent of perinatally exposed infants and children who acquire HCV infection.

The recommendations supplement those of 2020 for universal hepatitis C screening among adults, which includes universal screening of pregnant persons during each pregnancy, and they update guidance from 1998 on the type and timing of indicated testing as that technology has evolved.

The 4 primary recommendations:

  1. HCV testing of all perinatally exposed infants with a nucleic acid test (NAT) for detection of HCV RNA aged 2 to 6 months
  2. Consultation with a health care provider with expertise in pediatric hepatitis C management for all infants and children with detectable HCV RNA
  3. Perinatally exposed infants and children with an undetectable HCV RNA result at or after age 2 months do not require further follow-up unless clinically warranted.
  4. A NAT (nucleic acid test) for HCV RNA is recommended for perinatally exposed children aged 18 months or older who previously have not been tested.

Perinatal exposure occurs in infants born to pregnant persons with detectable HCV RNA, in testing which Panagiotakopoulos and colleagues acknowledge is not consistently obtained during pregnancy.

"Because recommendations have recently shifted from risk-based to universal screening, uptake of HCV screening during pregnancy is evolving," they commented.

What You Should Know

  • The CDC emphasizes the importance of testing all perinatally exposed infants for the hepatitis C virus (HCV) using a nucleic acid test (NAT) to detect HCV RNA between the ages of 2 and 6 months.
  • Infants and children with undetectable HCV RNA at or after age 2 months do not require further follow-up unless clinically warranted, streamlining interventions for those who do not test positive.
  • The recommendations highlight factors affecting HCV transmission, such as the association with poorly controlled HIV coinfection, the impact of antiretroviral therapy for HIV during pregnancy, and various aspects of delivery.

Panogiotakopoulos and colleagues note that transmission occurs more frequently with poorly controlled HIV coinfection, which might be more common in pregnant persons injecting drugs. They also indicate that the use of antiretroviral therapy for HIV during pregnancy to lower HIV viral load is associated with lower rates of perinatal HCV transmission.

Several aspects of transmission are considered, including that HCV transmission risk is increased with membrane rupture lasting more than 6 hours before delivery and with the use of internal fetal monitoring. Panogiotakopoulos and colleagues also note that amniocentesis is usually recommended over chorionic villus sampling when invasive testing is indicated.

There is no evidence, they point out, that caesarean delivery is less likely than vaginal delivery to prevent perinatal HCV transmission. Breastfeeding after delivery is also not associated with an increased risk of HCV transmission unless nipples are cracked or bleeding.

Recognizing that costs are a barrier to treatment, the recommendations include cost-effectiveness calculations: costs and health outcomes of various testing strategies incorporated rates of spontaneous clearance of infection. Outcomes had diagnosed infections, treated or cured infections, hepatocellular carcinoma, liver transplants, and liver-related deaths. Among several modeling studies, testing known perinatally exposed infants with a NAT (nucleic acid test) for HCV RNA at age 2 to 6 months was determined to achieve both cost-savings and improve health outcomes.

"Better understanding is needed regarding how to improve linkage to care for these infants. Specifically, barriers to testing and reasons why testing is not done and identified children are not referred to appropriate providers for follow-up," Panogiotakopoulos and colleagues urge.


1. Panagiotakopoulos L, Sandul AI, Conners EE, et al. CDC Recommendations for hepatitis C testing among perinatally exposed infants and children—United States, 2023. MMWR. 2023; 72(4):1-19.

Related Videos
Andrea Flinchum, 2024 president of the Certification Board of Infection Control and Epidemiology, Inc (CBIC) explains the AL-CIP Certification at APIC24
Association for Professionals in Infection Control and Epidemiology  (Image credit: APIC)
Lila Price, CRCST, CER, CHL, the interim manager for HealthTrust Workforce Solutions; and Dannie O. Smith III, BSc, CSPDT, CRCST, CHL, CIS, CER, founder of Surgicaltrey, LLC, and a central processing educator for Valley Health System
Jill Holdsworth, MS, CIC, FAPIC, CRCSR, NREMT, CHL, and Katie Belski, BSHCA, CRCST, CHL, CIS
Baby visiting a pediatric facility  (Adobe Stock 448959249 by
Antimicrobial Resistance (Adobe Stock unknown)
Anne Meneghetti, MD, speaking with Infection Control Today
Patient Safety: Infection Control Today's Trending Topic for March
Infection Control Today® (ICT®) talks with John Kimsey, vice president of processing optimization and customer success for Steris.
Related Content